Australia Epigenetics Market Size & Outlook, 2023-2030
Australia epigenetics market, 2018-2030 (US$M)
Related Markets
Australia epigenetics market highlights
- The Australia epigenetics market generated a revenue of USD 512.9 million in 2023 and is expected to reach USD 1,553.9 million by 2030.
- The Australia market is expected to grow at a CAGR of 17.2% from 2024 to 2030.
- In terms of segment, reagents was the largest revenue generating product in 2023.
- Services is the most lucrative product segment registering the fastest growth during the forecast period.
Epigenetics market data book summary
| Market revenue in 2023 | USD 512.9 million |
| Market revenue in 2030 | USD 1,553.9 million |
| Growth rate | 17.2% (CAGR from 2023 to 2030) |
| Largest segment | Reagents |
| Fastest growing segment | Services |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Reagents, Kits, Instruments, Enzymes, Services |
| Key market players worldwide | Roche Holding AG, Thermo Fisher Scientific Inc, Eisai Co Ltd, Novartis AG ADR, Element Biosciences, Dovetail Genomics, Illumina Inc, Promega, Abcam PLC |
Other key industry trends
- In terms of revenue, Australia accounted for 3.5% of the global epigenetics market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, China epigenetics market is projected to lead the regional market in terms of revenue in 2030.
- India is the fastest growing regional market in Asia Pacific and is projected to reach USD 1,635.4 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Epigenetics Market Scope
Epigenetics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Australia epigenetics market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to epigenetics market will help companies and investors design strategic landscapes.
Reagents was the largest segment with a revenue share of 34.57% in 2023. Horizon Databook has segmented the Australia epigenetics market based on reagents, kits, instruments, enzymes, services covering the revenue growth of each sub-segment from 2018 to 2030.
The epigenetics market in Australia is primarily driven by the rising prevalence of genetic disorders, such as cancer, cystic fibrosis, and sickle cell anemia. According to the Australian Bureau of Statistics article in 2022, about 1.8% of the population, equivalent to 456,200 individuals, were diagnosed with cancer.
The demand for gene-editing technologies to tackle these diseases is increasing rapidly, which is expected to boost the epigenetics market growth in the country. Furthermore, the presence of a well-established biotechnology industry in Australia is contributing to the development and the adoption of epigenetics-based therapies.
The Australian government recognizes the potential of epigenetics technology and provides various research grants & initiatives. This includes investments in research facilities, collaboration programs, and regulatory guidance development. These factors are expected to support market growth over the forecast period.
Reasons to subscribe to Australia epigenetics market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Australia epigenetics market databook
-
Our clientele includes a mix of epigenetics market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Australia epigenetics market , including forecasts for subscribers. This country databook contains high-level insights into Australia epigenetics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Australia epigenetics market size, by product, 2018-2030 (US$M)
Australia Epigenetics Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
